Daniel F Ortwine from Williamsburg, MI, age 69

Resumes

Daniel Ortwine

view source

Us Patents

Hydroxamic Acid Compounds Useful As Matrix Metalloproteinase Inhibitors
view source
US Patent:

6677355, Jan 13, 2004
Filed:

Feb 13, 2002
Appl. No.:

10/049544
Inventors:

Christopher Alan Conrad - Allegan MI
Patrick Michael OBrien - Stockbridge MI
Daniel Fred Ortwine - Saline MI
Joseph Armand Picard - Canton MI
Drago Robert Sliskovic - Saline MI
Assignee:

Warner-Lambert Company - Morris Plains NJ
International Classification:

C07D30791
US Classification:

514320, 514422, 514432, 514459, 514468, 546195, 548531, 549 28, 549414, 549419
Abstract:

Compounds of the formula; are useful for inhibiting matrix metalloproteinase enzymes in animals, and as such, prevent and treat diseases resulting from the breakdown of connective tissues. Also disclosed are methods for the preparation of such compounds, pharmaceutical compositions including the same, and methods of treating diseases in which matrix metalloproteinases are involved including multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurysm, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, osteoporosis, rheumatoid or osteoarthritis, renal disease, left ventricular dilation, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

Pyridine Matrix Metalloproteinase Inhibitors
view source
US Patent:

6881743, Apr 19, 2005
Filed:

Feb 8, 2002
Appl. No.:

10/071073
Inventors:

Nicole Chantel Barvian - Ann Arbor MI, US
David Thomas Connor - Ann Arbor MI, US
Patrick Michael O'Brien - Stockbridge MI, US
Daniel Fred Ortwine - Saline MI, US
William Chester Patt - Chelsea MI, US
Kevon Ray Shuler - Chelsea MI, US
Michael William Wilson - Ann Arbor MI, US
Assignee:

Warner-Lambert Company - Morris Plains NJ
International Classification:

A61K031/4412
C07D405/12
US Classification:

514338, 5462841
Abstract:

Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof,.

Chromone Derivatives As Matrix Metalloproteinase Inhibitors
view source
US Patent:

6908917, Jun 21, 2005
Filed:

Aug 5, 2003
Appl. No.:

10/634718
Inventors:

Daniel Fred Ortwine - Saline MI, US
Assignee:

Warner-Lambert Company - Morris Plains NJ
International Classification:

C07D265/22
C07D311/22
A61K031/536
A61K031/352
A61K019/02
US Classification:

5142305, 544 92, 549399
Abstract:

This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof,wherein R, Q, Y, Y, Y, U, U, U, and Rare as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

Pyridine Matrix Metalloproteinase Inhibitors
view source
US Patent:

7015237, Mar 21, 2006
Filed:

May 10, 2004
Appl. No.:

10/842863
Inventors:

Nicole Chantel Barvian - Ann Arbor MI, US
David Thomas Connor - Ann Arbor MI, US
Patrick Michael O'Brien - Stockbridge MI, US
Daniel Fred Ortwine - Saline MI, US
William Chester Patt - Chelsea MI, US
Michael William Wilson - Ann Arbor MI, US
Assignee:

Warner-Lambert Company - Morris Plains NJ
International Classification:

A61K 31/4412
C07D 213/53
US Classification:

514354, 514352, 514344, 514348, 514349, 514350, 546286, 546287, 546288, 546289, 546296, 546297, 546300, 546308, 546309, 546323
Abstract:

Selective MMP-13 inhibitors are pyridine derivatives of the formula or a pharmaceutically acceptable salt thereof,wherein:.

5-Substituted-4-[(Substituted Phenyl) Amino]-2-Pyridone Derivatives
view source
US Patent:

7273877, Sep 25, 2007
Filed:

Jun 24, 2004
Appl. No.:

10/876100
Inventors:

Shannon Leigh Black - Heidelberg, DE
Michael David Kaufman - Ypsilanti MI, US
Daniel Fred Ortwine - Saline MI, US
Mark Stephen Plummer - Dexter MI, US
John Quin, III - Ann Arbor MI, US
Gordon William Rewcastle - Auckland, NZ
Aurash B. Shahripour - Ann Arbor MI, US
Julie Ann Spicer - Auckland, NZ
Christopher Emil Whitehead - Ypsilanti MI, US
Assignee:

Warner-Lambert Company, LLC - Morris Plains NJ
International Classification:

A61K 31/4439
C07D 413/04
C07D 213/72
US Classification:

514340, 514349, 5462694, 546297
Abstract:

The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

Pyrimidine Compounds, Compositions And Methods Of Use
view source
US Patent:

8163763, Apr 24, 2012
Filed:

Jul 31, 2009
Appl. No.:

12/533935
Inventors:

Philippe Bergeron - San Francisco CA, US
Frederick Cohen - San Francisco CA, US
Anthony Estrada - San Carlos CA, US
Michael F. T. Koehler - Palo Alto CA, US
Kevin Hon Luen Lau - San Mateo CA, US
Cuong Ly - Daly City CA, US
Joseph P. Lyssikatos - Piedmont CA, US
Daniel Ortwine - San Ramon CA, US
Zhonghua Pei - Burlingame CA, US
Xianrui Zhao - San Mateo CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

A61K 31/519
C07D 471/04
US Classification:

5142641, 544279
Abstract:

Disclosed are compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e. g. , mTOR, and for the treatment of diseases (e. g. , cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e. g. , mTOR).

Pyridazinones, Method Of Making, And Method Of Use Thereof
view source
US Patent:

8598174, Dec 3, 2013
Filed:

Nov 12, 2009
Appl. No.:

13/128726
Inventors:

Antonio J. M. Barbosa, Jr. - Middlebury CT, US
Peter A. Blomgren - North Branford CT, US
Kevin S. Currie - North Branford CT, US
Seung Lee - Branford CT, US
Jeffrey E. Kropf - Branford CT, US
Scott A. Mitchell - East Haven CT, US
Daniel Ortwine - San Ramon CA, US
William M. Rennells - Schenectady NY, US
Aaron C. Schmitt - Hamden CT, US
Jianjun Xu - Madison CT, US
Wendy B. Young - San Mateo CA, US
Zhongdong Zhao - Guilford CT, US
Pavel E. Zhichkin - Delmar NY, US
Assignee:

Genetech, Inc. - South San Francisco CA
Gilead Connecticut, Inc. - Foster City CA
International Classification:

A61K 31/50
A61K 31/501
C07D 237/30
US Classification:

51425201, 544224
Abstract:

Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

Pyridone And Aza-Pyridone Compounds And Methods Of Use
view source
US Patent:

8618107, Dec 31, 2013
Filed:

May 6, 2011
Appl. No.:

13/102720
Inventors:

Antonio J. M. Barbosa - Middlebury CT, US
Peter A. Blomgren - North Branford CT, US
Kevin S. Currie - North Branford CT, US
Ravi Krishnamoorthy - Guilderland NY, US
Jeffrey E. Kropf - Branford CT, US
Seung H. Lee - Branford CT, US
Scott A. Mitchell - East Haven CT, US
Daniel Ortwine - San Ramon CA, US
Aaron C. Schmitt - Hamden CT, US
Xiaojing Wang - Foster City CA, US
Jianjun Xu - Madison CT, US
Wendy Young - San Mateo CA, US
Honglu Zhang - Guilderland NY, US
Zhongdong Zhao - Guilford CT, US
Pavel E. Zhichkin - Delmar NY, US
Assignee:

Gilead Connecticut, Inc. - Foster City CA
Genentech, Inc. - South San Francisco CA
International Classification:

A61K 31/50
A61K 31/501
C07D 487/00
US Classification:

51425201, 544236
Abstract:

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.